Evidence map›Paper›PMID 38253462›Full record

ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2024

Protein-Protein interactive networks identified in bronchoalveolar lavage of severe compared to nonsevere asthma.

Annette T Hastie, Andrew C Bishop, Mohammad S Khan, Eugene R Bleecker, Mario Castro, Loren C Denlinger, Serpil C Erzurum, John V Fahy, Elliot Israel, Bruce D Levy and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Asthma endotypes and theratypes.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Annette T HastieDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.ORCID https://orcid.org/0000-0001-6607-7797
Andrew C BishopDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Mohammad S KhanDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Eugene R BleeckerDepartment of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Mario CastroDepartment of Pulmonary, Critical Care and Sleep Medicine, Kansas University Medical Center, Kansas City, Kansas, USA.
Loren C DenlingerDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Serpil C ErzurumDepartment of Pulmonary Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
John V FahyDepartment of Pulmonary and Critical Care Medicine, University of California-San Francisco, San Francisco, California, USA.
Elliot IsraelDepartment of Medicine, Brigham and Womens Hospital, Boston, Massachusetts, USA.
Bruce D LevyDepartment of Medicine, Brigham and Womens Hospital, Boston, Massachusetts, USA.
David T MaugerCenter for Biostatistics and Epidemiology, Penn State School of Medicine, Hershey, Pennsylvania, USA.
Deborah A MeyersDepartment of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Wendy C MooreDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Victor E OrtegaDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Stephen P PetersDepartment of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Sally E WenzelThe University of Pittsburgh Asthma Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Chad H SteeleDepartment of Microbiology and Immunology, School of Medicine, Tulane University, New Orleans, Louisiana, USA.
Wake Forest University · USMayo Clinic in Arizona · USBrigham and Women's Hospital · USCleveland Clinic · USPenn State Milton S. Hershey Medical Center · USTulane University · USUniversity Medical Center · USUniversity of California, San Francisco · USUniversity of Pittsburgh · USUniversity of Wisconsin–Madison · US

Funding

Clinical Coordinating Center for the Severe Asthma Research Program (SARP)U10HL109086 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MAUGER, DAVID T. · 2011 to 2017
$8.1M
Immunopathogenesis in fungal asthmaR01HL122426 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Chad Steele · 2015 to 2026
$5.1M
AMSA: ALXR/FBR Mediated Signaling in Severe AsthmaU10HL109172 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ISRAEL, ELLIOT, LEVY, BRUCE D · 2011 to 2016
$4.2M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
Clinical and Molecular Phenotypes of Severe AsthmaU10HL109146 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2011 to 2016
$4.0M
Implications and Stability of Clinical and Molecular Phenotypes of Severe AsthmaU10HL109152 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WENZEL, SALLY E · 2011 to 2016
$3.9M
Stability of Severe Asthma Phenotypes: Impact of ExacerbationsU10HL109168 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI JARJOUR, NIZAR N · 2011 to 2016
$3.9M
Severe Asthma Research Program (SARP)-Washington UniversityU10HL109257 · NHLBI · WASHINGTON UNIVERSITY · PI CASTRO, MARIO · 2011 to 2016
$3.8M
Longitudinal Phenomics and Genetics of Severe AsthmaU10HL109164 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BLEECKER, EUGENE ROLAND, MEYERS, DEBORAH A. · 2011 to 2016
$3.8M
NHLBI NIH HHS R01 HL122426NHLBI NIH HHS U10 HL109086NHLBI NIH HHS U10 HL109146NHLBI NIH HHS U10 HL109152NHLBI NIH HHS U10 HL109164NHLBI NIH HHS U10 HL109168NHLBI NIH HHS U10 HL109172NHLBI NIH HHS U10 HL109250NHLBI NIH HHS U10 HL109257
6 · The paper itself

Abstract

introductionPrevious bronchoalveolar lavage fluid (BALF) proteomic analysis has evaluated limited numbers of subjects for only a few proteins of interest, which may differ between asthma and normal controls. Our objective was to examine a more comprehensive inflammatory biomarker panel in quantitative proteomic analysis for a large asthma cohort to identify molecular phenotypes distinguishing severe from nonsevere asthma.

methodsBronchoalveolar lavage fluid from 48 severe and 77 nonsevere adult asthma subjects were assessed for 75 inflammatory proteins, normalized to BALF total protein concentration. Validation of BALF differences was sought through equivalent protein analysis of autologous sputum. Subjects' data, stratified by asthma severity, were analysed by standard statistical tests, principal component analysis and 5 machine learning algorithms.

resultsThe severe group had lower lung function and greater health care utilization. Significantly increased BALF proteins for severe asthma compared to nonsevere asthma were fibroblast growth factor 2 (FGF2), TGFα, IL1Ra, IL2, IL4, CCL8, CCL13 and CXCL7 and significantly decreased were platelet-derived growth factor a-a dimer (PDGFaa), vascular endothelial growth factor (VEGF), interleukin 5 (IL5), CCL17, CCL22, CXCL9 and CXCL10. Four protein differences were replicated in sputum. FGF2, PDGFaa and CXCL7 were independently identified by 5 machine learning algorithms as the most important variables for discriminating severe and nonsevere asthma. Increased and decreased proteins identified for the severe cluster showed significant protein-protein interactions for chemokine and cytokine signalling, growth factor activity, and eosinophil and neutrophil chemotaxis differing between subjects with severe and nonsevere asthma.

conclusionThese inflammatory protein results confirm altered airway remodelling and cytokine/chemokine activity recruiting leukocytes into the airways of severe compared to nonsevere asthma as important processes even in stable status.

Indexed as

AsthmaVascular Endothelial Growth Factor AAdultBronchoalveolar LavageBronchoalveolar Lavage FluidChemokinesCytokinesFibroblast Growth Factor 2HumansProteomicsChemokinesCytokinesFibroblast Growth Factor 2Vascular Endothelial Growth Factor Abronchoalveolar lavage fluidchemokinescytokinesgrowth factorsmachine learningsevere asthma

Identifiers

PMID38253462
PMCPMC11075125
OpenAlexW4391116161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.